To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors

NCT03002493 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor

Interventions

DRUG: Eribulin mesylate
DRUG: Eribulin mesylate
DRUG: Rifampicin

Sponsor

Eisai Limited